Propranolol Recall: The Breckenridge Lot to Check and What Patients Should Do

post-img

A pharmacy professional at work in a 2019 archive photograph. The recalled propranolol product is not shown. Archive photo by M Joko Apriyo Putro (CC BY-SA 4.0).

A nationwide drug recall announced this week concerns a precisely identified batch of propranolol, a widely used prescription beta blocker. Breckenridge Pharmaceutical is recalling one lot of its 60 milligram extended-release capsules because of potential metal contamination. For patients, the immediate task is to establish whether the medicine dispensed by their pharmacy came from that lot and obtain prompt instructions about a replacement.

The affected product is Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, in 100-count bottles, NDC 51991-817-01, lot PK25110035, expiration May 2029. The company’s November 16 recall announcement says consumers should stop taking product from the recalled lot, contact their physician or other healthcare provider for medical advice and replacement instructions, and return unused affected medicine to the pharmacy. That direction concerns this lot; it is not an instruction for everyone prescribed propranolol to abandon treatment.

There is an additional reason to act promptly rather than improvise. Propranolol can be dangerous to discontinue abruptly without medical supervision. People who identify the recalled lot should contact their pharmacist and prescriber immediately to resolve both issues: removing suspect capsules and maintaining an appropriate treatment plan. Continuing recalled medicine, substituting someone else’s tablets or inventing a taper is not a safe way to bridge that conversation.

Which propranolol capsules are recalled?

Adare Pharma Solutions manufactured the affected capsules for Breckenridge. The company says the lot was distributed to wholesalers and pharmacies across the United States between October 26 and November 4, 2026. The concern arose because it shared an intermediate material suspected of causing metal contamination in another lot that was not released to the market. Breckenridge reported no adverse events assessed as related to the recall when it issued the notice. That statement describes the company’s information at that time, rather than establishing that every capsule is harmless.

A medication’s identity has several layers. Its generic name identifies the active ingredient, its strength identifies how much is present, and its formulation describes how the medicine releases that ingredient. The National Drug Code identifies a particular marketed product and package. A lot number narrows the identification further to a manufacturing batch. In a recall involving only one lot, matching the drug name or capsule color alone cannot answer whether a patient’s prescription is affected.

Many patients do not receive the manufacturer’s original 100-count container. Pharmacies commonly dispense a prescribed quantity into a smaller bottle with their own label. Someone holding a 30-capsule prescription therefore should not assume that the 100-count description excludes their medicine. The pharmacy that filled it is the practical starting point for determining which stock bottle supplied the prescription. A photograph of the pharmacy label can make that conversation easier, but the original lot may need to be checked in dispensing records or inventory.

The Breckenridge product labeling on DailyMed describes the 60 mg capsule as white and opaque, with “60” on the cap and “RD203” on the body. Those markings identify a product, not a unique batch. An unaffected lot can look the same. Conversely, a repackaged medicine may carry a different outer label. The most useful question is specific: can the pharmacy establish whether this prescription came from the recalled Breckenridge lot? An answer based only on the appearance of the capsule is incomplete.

The announcement does not automatically include every propranolol brand, strength or formulation. Immediate-release tablets and extended-release capsules should not be treated as interchangeable descriptions. A patient who takes an 80 mg product, for example, should verify any concerns with a pharmacist rather than transfer a warning about this 60 mg batch to a different prescription. Precise identification prevents a limited manufacturing problem from turning into unnecessary disruption of unrelated treatment.

Why the contamination warning and the treatment warning both matter

Breckenridge identifies possible cuts to soft tissue in the mouth and digestive tract as the risk from the suspected contamination. The notice does not establish how many individual capsules contain material or offer a home inspection method that can reliably clear a bottle for use. An apparently normal capsule is therefore not a substitute for checking its lot. Nor should a patient open or alter extended-release capsules in an effort to search for contamination.

Propranolol belongs to a different category of risk when treatment changes suddenly. MedlinePlus, the National Library of Medicine’s drug information service, warns that abrupt discontinuation can cause serious heart problems. The medicine has several uses, and a patient’s underlying condition, dose and other prescriptions all affect the appropriate response. A general news report cannot supply an individual withdrawal or replacement schedule.

These warnings can sound contradictory when compressed into a social media post. They address different problems. The manufacturer is telling consumers to remove identified suspect product from use. Clinical guidance explains why stopping a beta blocker without a coordinated plan can also be hazardous. The practical response is urgent communication with the people who can supply an unaffected medicine and direct its use, rather than choosing one warning and ignoring the other.

Patients calling a pharmacy should have their prescription number, product name, strength and dispensing date available. They can ask whether the source lot was affected, whether an unaffected supply can be arranged, and how the prescriber will be contacted if treatment instructions are needed. A person who is close to the next scheduled dose should say so at the beginning of the call. That detail helps communicate urgency without requiring the patient to make a medical decision alone.

Anyone experiencing severe or alarming symptoms should seek urgent medical care rather than wait for a routine recall inquiry to be returned. A recall service can help identify and return a product, but it does not replace emergency assessment or the clinician responsible for a patient’s condition. Bringing the medication container, or a clear picture of its label when appropriate, can help healthcare professionals understand what was taken.

What pharmacies and households should do with the notice

For pharmacies, the recall is both an inventory issue and a communication issue. Stock associated with the affected lot needs to be separated from saleable supply, and patients who may have received it need clear, usable information. A broad message saying a blood pressure drug has been recalled can draw attention, but it leaves the central question unanswered. Patients need to know whether their own prescription is involved and what the next step will be.

The FDA’s drug recall information explains the wider system through which defective products are removed or corrected. A voluntary recall is still a formal product action; the word voluntary does not mean an affected patient can disregard it. Equally, the existence of a recall does not mean that every product made by a company, or every medicine in the same therapeutic class, has the same defect. Scope is determined by the actual notice and any subsequent expansion.

At home, keeping the affected bottle and its label available can preserve information needed for verification and return. Patients should follow the pharmacy’s instructions about bringing medicine back rather than casually disposing of it before the lot is established. They should also avoid mixing capsules from different prescriptions in one container. Once identifying information is lost, it becomes harder to distinguish a recalled supply from a replacement.

Families helping an older relative can make the process less confusing by checking the medicine together and recording the pharmacy’s answer. If more than one person in a household takes propranolol, each prescription needs its own verification. Two bottles filled at different times or locations may have different sources. The same applies to a medicine organizer: knowing which prescription supplied the capsules matters more than the day of the week printed on its lid.

Breckenridge lists Qualanex as its recall service provider, reachable at 1-855-736-0807, Monday through Friday, 9 a.m. to 5 p.m. Eastern Time. That service is for recall questions. A prescriber or pharmacist should handle questions about an individual treatment plan. Keeping those roles distinct can save patients from being transferred repeatedly while an important clinical question remains unresolved.

A useful recall response ends with an answer about your bottle

Patients and healthcare professionals can report suspected adverse reactions or product quality problems through the FDA’s MedWatch program. A useful report identifies the medicine, manufacturer when known, lot, timing of use and the problem observed. Reporting a concern is not the same as proving that a medicine caused it; it supplies information for investigation. Patients should still obtain medical care when needed and should not wait for a regulatory response before contacting their clinician.

This recall also illustrates why broad health headlines need careful reading. “Drug recall” may describe a manufacturing defect in a small part of the supply, a wider quality problem, or a change in advice about an ingredient. Those situations call for different actions. Here, the current notice gives a batch-specific reason for removal. It does not establish that propranolol as a treatment has become unsuitable for everyone who uses it.

For a patient who verifies that a bottle is unaffected, the next step is to follow the existing prescription unless their healthcare professional advises otherwise. For someone whose medicine matches the recalled lot, the priority is immediate contact and a medically appropriate replacement plan. For someone who cannot establish the lot, uncertainty is a reason to ask the dispensing pharmacy for help, rather than assume either safety or contamination from a headline.

The conclusion is concrete: check the exact product and batch, act on the manufacturer’s instruction for affected capsules, and coordinate treatment promptly with a pharmacist and prescriber. The recalled lot is PK25110035, with an expiration of May 2029. Accurate identification and a clear clinical plan are what turn a frightening national alert into a manageable response for the person holding the prescription.

About Us

The argument in favor of using filler text goes something like this: If you use arey real content in the Consulting Process anytime you reachtent.

Instagram

Cart